News | April 08, 2021
Zydus Cadila announces USFDA approval for Ibrutinib capsules
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis
He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
Subscribe To Our Newsletter & Stay Updated
